Overview
KLOW is a four-component compounded blend: BPC-157, TB-500, KPV and GHK-Cu. It is the GLOW blend (BPC-157 + TB-500 + GHK-Cu) with KPV added.
The four components are chosen to cover complementary mechanisms in tissue repair. BPC-157 is a gastric-derived pentadecapeptide studied for cytoprotection and angiogenic signalling. TB-500 is a thymosin beta-4 fragment associated with actin regulation and cell migration. GHK-Cu is the copper-binding tripeptide associated with extracellular matrix remodelling and collagen synthesis. KPV is the C-terminal tripeptide of alpha-MSH, studied for anti-inflammatory activity — and it is the addition that distinguishes KLOW from GLOW, supplying an explicitly anti-inflammatory arm alongside the repair-oriented components.
The design logic is coherent. What is missing is any evidence that the combination behaves as designed. No study of KLOW as a mixture was located. Each component's individual evidence base is itself largely preclinical, so the blend inherits four sets of open questions and adds the interaction question on top.
See our individual entries for BPC-157, TB-500, KPV and GHK-Cu, where each compound's evidence is set out on its own terms.
What the evidence shows
Separated by study type- HumanClinical trials and human studies
- No human studies of this combination.
- AnimalRodent and other animal models
- No studies of the combination located; component evidence is largely preclinical.
- In vitroCell and tissue studies
- No studies of the combination located.
Key studies & findings
1 study- 1
No study of the KLOW combination was located. Evidence exists for individual components at varying levels of quality, none of it transferable to the mixture.
Benefits & effects
1 documentedCombines four complementary proposed repair and anti-inflammatory mechanisms
Side effects & safety
2 reportedSafety noteCompounded blend of research compounds for laboratory use only. Premixed blends compound the unknowns of each component and add one of their own: if an adverse effect occurs, the responsible component cannot be identified.
Recorded in the cited literature No safety data for the combination.
Adverse effects cannot be attributed to a specific component
Components cannot be titrated independently
Limitations & open questions
This is a fixed-ratio premixed combination, and that carries specific consequences beyond those of its individual components. The components cannot be titrated independently — adjusting one means adjusting all of them. If a reaction occurs, attribution is impossible. And the combination itself has not been studied: evidence for the individual compounds does not transfer to the mixture, because combined pharmacology is not the sum of separate pharmacologies. Blends are a convenience and pricing format, not a validated pharmacological unit. KLOW specifically stacks four compounds whose individual evidence bases are themselves predominantly preclinical, so the uncertainty is multiplied rather than offset. The copper in GHK-Cu also raises a formulation question in a multi-component mixture that single-compound use does not.
Pharmacology
A mixture rather than a single chemical entity, so molecular formula, weight and CAS number do not apply. Component ratios vary between compounders and are not standardised. See the individual entries for each component's chemistry.
Frequently asked questions
What is the difference between KLOW and GLOW?
KPV. GLOW is BPC-157 + TB-500 + GHK-Cu; KLOW adds KPV, the C-terminal tripeptide of alpha-MSH, contributing an anti-inflammatory arm.
Is KLOW better than using the components separately?
There is no evidence either way, because the combination has not been studied. Separate components at least allow independent titration and attribution if something goes wrong, which a fixed-ratio blend does not.
Why do blends exist if they aren't studied?
Convenience and pricing — one vial, one reconstitution, one purchase. That is a practical rationale, not a pharmacological one.